Therapeutic Strategies for Fibrotic Diseases
AlphaScreen® SureFire® pERK and HTRF® cGMP kits were used to better u...
-->
Nonalcoholic fatty liver disease (NAFLD) remains a major cause of liver-related morbidity and mortality worldwide. This complex disease is associated with obesity, diabetes, and dyslipidemia, but has been increasingly recognized in normal-weight individuals. Explore our articles, news, literature reviews, tips, and more on NASH research.
AlphaScreen® SureFire® pERK and HTRF® cGMP kits were used to better u...
Discover how PIIINP ELISA test assesses NAFLD staging in children
Measuring circulating cardiac fibrosis markers in patients treated for h...
SERP1: a new GLP-1 receptor interactor
Investigation of atrial fibrosis in the pathogenesis of atrial fibrillat...
A marker for monitoring liver fibrosis in MTX-treated patients
A marker for monitoring kidney fibrosis risk in children with SFK
A marker for monitoring liver fibro-inflammation in Type 2 diabetes pati...
Exclusive symposium on NASH/Fibrosis challenges featuring key opinion le...